Placebo Administration Clinical Trials

29 recruitingDrug
Phase 224Phase 32Early Phase 12Phase 11Not Applicable1

Showing 120 of 29 trials

Recruiting
Phase 2

Placebo-Controlled Trial of Urolithin A Supplementation in Men With Prostate Cancer Undergoing Radical Prostatectomy, URO-PRO Trial

Prostate Adenocarcinoma
National Cancer Institute (NCI)90 enrolled5 locationsNCT06022822
Recruiting
Phase 2

Testing the Effect of the Broccoli Seed and Sprout Extract, Avmacol ES, on the Cancer Causing Substances of Tobacco in Heavy Smokers

Cigarette Smoking-Related Carcinoma
National Cancer Institute (NCI)135 enrolled3 locationsNCT05121051
Recruiting
Phase 2

Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery

Recurrent Mucosal MelanomaMucosal MelanomaAnal Melanoma+14 more
National Cancer Institute (NCI)101 enrolled147 locationsNCT05111574
Recruiting
Phase 2

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

Pancreatic Acinar Cell CarcinomaResectable Pancreatic CarcinomaResectable Pancreatic Adenocarcinoma+4 more
National Cancer Institute (NCI)152 enrolled454 locationsNCT04858334
Recruiting
Phase 2

Obeticholic Acid for Prevention in Barrett's Esophagus

Esophageal AdenocarcinomaBarrett Esophagus
National Cancer Institute (NCI)30 enrolled8 locationsNCT04939051
Recruiting
Phase 1Phase 2

Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer

Stage III Pancreatic Cancer AJCC v8Locally Advanced Pancreatic Adenocarcinoma
National Cancer Institute (NCI)92 enrolled44 locationsNCT04172532
Recruiting
Phase 2

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

Acute Myeloid LeukemiaMyelodysplastic SyndromeAcute Myeloid Leukemia Post Cytotoxic Therapy+2 more
National Cancer Institute (NCI)2,000 enrolled345 locationsNCT05564390
Recruiting
Phase 2

Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer

Head and Neck Squamous Cell CarcinomaStage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8+38 more
NRG Oncology98 enrolled149 locationsNCT06532279
Recruiting
Phase 3

Wisconsin Ginseng for Decreasing Cancer Related Fatigue

Malignant Solid Neoplasm
Mayo Clinic160 enrolled15 locationsNCT06395441
Recruiting
Phase 2

Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms

Myelodysplastic SyndromeMyelofibrosisPolycythemia Vera+2 more
University of Southern California30 enrolled2 locationsNCT06063486
Recruiting
Phase 2

Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

Chronic Myelomonocytic LeukemiaRecurrent LymphomaRecurrent Diffuse Large B-Cell Lymphoma+5 more
Mayo Clinic80 enrolled4 locationsNCT03418038
Recruiting
Phase 2

EMLA Topical Cream for Treatment of Pain in Patients Receiving Intra-Dermal Technetium 99 Injections for Lymphoscintigraphy for Skin Cancers

Skin Squamous Cell CarcinomaMerkel Cell CarcinomaCutaneous Melanoma
Ohio State University Comprehensive Cancer Center100 enrolled1 locationNCT06223659
Recruiting
Phase 2

CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaChronic Lymphocytic Leukemia+7 more
City of Hope Medical Center216 enrolled3 locationsNCT06059391
Recruiting
Phase 2

Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Exposure to High-Risk Antibiotics Who Are Receiving Chimeric Antigen Receptor T Cells

Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsRefractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsRecurrent Diffuse Large B-Cell Lymphoma+3 more
City of Hope Medical Center56 enrolled1 locationNCT07042438
Recruiting
Phase 2

Fucoidan for Preventing Chemotherapy-Related Fatigue in Patients With Gastrointestinal or Gynecological Cancer

Malignant Female Reproductive System NeoplasmMalignant Digestive System Neoplasm
Mayo Clinic34 enrolled1 locationNCT06855524
Recruiting
Phase 2

Belumosudil for the Pre-emptive Treatment of Patients With Chronic Graft Versus Host Disease

Chronic Graft Versus Host Disease
Fred Hutchinson Cancer Center82 enrolled4 locationsNCT05996627
Recruiting
Early Phase 1

Effects of a Probiotic Intervention on the Gut and Vaginal Microbiome in Patients With Advanced or Recurrent Ovarian Cancer Undergoing Treatment With Platinum Chemotherapy

Recurrent Ovarian CarcinomaStage III Ovarian Cancer AJCC v8Stage IV Ovarian Cancer AJCC v8+2 more
Ohio State University Comprehensive Cancer Center161 enrolled1 locationNCT07144826
Recruiting
Phase 2

Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancreaticobiliary, Colorectal or Lung Cancer

Locally Advanced Hepatocellular CarcinomaLocally Advanced Gastric CarcinomaAdvanced Biliary Tract Carcinoma+7 more
OHSU Knight Cancer Institute66 enrolled1 locationNCT05705492
Recruiting
Phase 3

Vitamin D for Prostate Endocrine Therapy

Stage III Prostate Cancer AJCC v8Stage I Prostate Cancer AJCC v8Stage II Prostate Cancer AJCC v8+1 more
University of Rochester240 enrolled51 locationsNCT05838716
Recruiting
Phase 2

Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study

Stage IVB Prostate Cancer AJCC v8Prostate AdenocarcinomaOligometastatic Prostate Carcinoma+2 more
NRG Oncology194 enrolled239 locationsNCT05053152